A record of how the explosive momentum from vaccine clinical trial success led to an unexpected major rally

Reviewing Prediction vs. Actual Result

Entered the position with a projected return of 4.5% in view, but the actual outcome recorded a massive surge of 131.2%, earning an OVERHIT verdict. The entry decision was driven by the powerful catalyst of a successful melanoma vaccine clinical trial and a volatility rate of +6.4%; however, the technical indicators at the time—RSI of 67.2, trading volume at 0.80x the 20-day average, and non-aligned moving averages—made it difficult to fully gauge the magnitude of such explosive upward momentum. The market had formed a far greater wave of buying pressure that went well beyond a simple reaction to the positive news.

What to Watch in the Next Analysis

Through this trade, I was reminded that when a major biotech catalyst breaks out, even if technical indicators (such as an RSI of 67.2 or a low volume ratio) appear somewhat conservative, one must be careful not to underestimate the explosive impact that a fundamental catalyst like a strong clinical success can deliver. Going forward, when trading similar bio-sector events, I should avoid being bound solely by the resistance levels or conservative readings of initial indicators, and instead establish a flexible profit-taking strategy that leaves room for the catalyst's ripple effects and the theme's potential transition to S-Class.